Return
Discovery and Optimization of Novel TEAD Inhibitors for In Vivo Investigation Against Hepatocellular Carcinoma
D
W
Y
X
Y
S
Y
C
C
G
Y
S
H
DOI:10.1016/j.ejmech.2026.118886.png)
Abstract
En 中文
• Cyclization strategy was employed to yield a novel scaffold targeting TEAD palmitate-binding pocket. • Comprehensive and systematic structure-activity relationship (SAR) analysis was conducted. • Optimized compound LC-TD-05 displayed favorable oral bioavailability (F=53.7%). • Compound LC-TD-05 exhibited significant antitumor activity in both in vitro and in vivo HCC models.
Keywords:
TEAD inhibitors
cyclization strategy
hepatocellular carcinoma
structure-activity relationship
oral bioavailability
Journal
IF:
5.9
Papers:
1.7W
Citations:
6.0W
